Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.96 |
| ▸ | ACE known ✓ | P12821 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | MME | P08473 | 6/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4649258 | 1.00 | GAA (0.96) | GAAMAPTMMEACESMYD3 | |
| Hydrochloric Acid SCHEMBL2521107 | 1.00 | GAA (0.96) | GAAMAPTMMEACESMYD3 | |
| SCHEMBL14003020 | 0.98 | GAA (1.00) | GAAMAPTMMEACESMYD3 | |
| SCHEMBL926388 | 0.98 | GAA (1.00) | GAAMAPTMMEACESMYD3 | |
| SCHEMBL29495388 | 0.98 | GAA (1.00) | GAAMAPTMMEACESMYD3 | |
| SCHEMBL29365197 | 0.98 | GAA (1.00) | GAAMAPTMMEACESMYD3 | |
| SCHEMBL91080 | 0.98 | GAA (1.00) | GAAMAPTMMEACESMYD3 | |
| SCHEMBL1134239 | 0.98 | GAA (1.00) | GAAMAPTMMEACESMYD3 | |
| SCHEMBL27571214 | 0.96 | GAA (0.96) | GAAMAPTMMEACESMYD3 | |
| Chlorolithium SCHEMBL27888952 | 0.95 | GAA (0.87) | GAAMAPTMMEACESMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3475284-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS INC (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-3475284-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | Mersana Therapeutics, Inc. (US) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017223275-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170369453-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9849112-B2 | Pyrrole compounds as Granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2017-12-26 | — | — | US | disclosed |
| US-20170015705-A1 | PYRROLE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2017-01-19 | — | — | US | disclosed |
| US-9458138-B1 | Pyrrole compounds as granzyme B inhibitors | viDATherapeutics Inc. (CA) | 2016-10-04 | — | — | US | disclosed |
| CN-101316838-B | 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as h3 modulators | HOFFMANN LA ROCHE | 2013-01-30 | — | — | CN | disclosed |
| CN-101316840-B | 1, 5-substituted indol-2-yl amide derivatives | HOFFMANN LA ROCHE | 2012-08-08 | — | — | CN | disclosed |
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2011-10-13 | — | — | US | disclosed |
| WO-2003072528-A2 | (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| US-20020091089-A1 | (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | KARANEWSKY DONALD S (US) | 2002-07-11 | — | — | US | disclosed |
| EP-1123272-A1 | (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | Idun Pharmaceuticals, Inc. (US) | 2001-08-16 | — | — | EP | disclosed |
| US-6242422-B1 | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases | IDUN PHARMACUETICALS, INC. | 2001-06-05 | — | — | US | disclosed |
| WO-2000023421-A1 | (SUBSTITUTED)ACYL DIPEPTIDYL INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
| WO-1993020099-A2 | CCK AND/OR GASTRIN RECEPTOR LIGANDS | FERRING B.V. (NL) | 1993-10-14 | — | — | WO | disclosed |
| US-4678800-A | INHIBITORS OF ANGIOTENSIN-CONVERTING ENZYME | CIBA-GEIGY CORPORATION (US) | 1987-07-07 | — | — | US | disclosed |
| US-4599357-A | 1-mercaptoalkanoylindoline-2-carboxylic acids | CIBA-GEIGY CORPORATION (US) | 1986-07-08 | — | — | US | disclosed |
| US-4479963-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1984-10-30 | — | — | US | disclosed |
| US-4374847-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1983-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | GAA 1615/4885ACE 3349/4885MAPT 3328/4885 |
| US-20020091089-A1 | (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases | DPP3, IAPP, CASP3 | GAA 1237/4885ACE 209/4885MAPT 348/4885 |
| US-20170015705-A1 | PYRROLE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, CTSB, DNASE1L3 | GAA 131/4885ACE 2311/4885MAPT 3222/4885 |
| US-20170369453-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | GAA 1088/4885ACE 3769/4885MAPT 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.